The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2018 Release

February 20, 2018EISAI CERTIFIED IN 2018 AS OUTSTANDING HEALTH AND PRODUCTIVITY MANAGEMENT ORGANIZATION (WHITE 500)
February 16, 2018U.K. NICE RECOMMENDS ANTICANCER AGENT LENVIMA® AS TREATMENT FOR THYROID CANCER
February 10, 2018PHASE III TRIAL RESULTS OF ANTICANCER AGENT LENVATINIB IN HEPATOCELLULAR CARCINOMA PUBLISHED IN THE LANCET
February 9, 2018EISAI CONTRIBUTES TO TAIWAN EARTHQUAKE RELIEF EFFORTS
February 1, 2018 PRIMARY ENDPOINT MET IN PHASE II / III CLINICAL STUDY OF INVESTIGATIONAL PARKINSON'S DISEASE TREATMENT SAFINAMIDE IN JAPAN
January 22, 2018 EISAI PRESENTS RESULTS OF ANALYSIS OF PHASE III TRIAL OF LENVIMA® (LENVATINIB) IN HEPATOCELLULAR CARCINOMA BASED ON INDEPENDENT IMAGING REVIEW AT ASCO-GI
January 19, 2018 New drug approval of bile acid transporter inhibitor “GOOFICE® 5mg Tablet” for chronic constipation was obtained in Japan.
January 19, 2018 ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN
January 19, 2018 EISAI ENTERS INTO LICENSING AGREEMENT WITH ADLAI NORTYE FOR POTENTIAL ANTICANCER AGENT E7046 (PROSTAGLANDIN E2 RECEPTOR TYPE 4 ANTAGONIST)
January 18, 2018 PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES
January 11, 2018 EISAI COMPLETES CONSTRUCTION OF ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
January 9, 2018 BIOGEN AND EISAI COMMENCE CO-PROMOTION OF MULTIPLE SCLEROSIS TREATMENTS IN JAPAN
January 9, 2018 Eisai and Merck & Co., Inc., Kenilworth, N.J., USA. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma

Back to Top

2017 Release

December 27, 2017 ANTICANCER AGENT LENVATINIB DESIGNATED FOR PRIORITY REVIEW AND APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION FOR HEPATOCELLULAR CARCINOMA
December 21, 2017 ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER'S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS OF ADCOMS NOT MET

STUDY TO REMAIN BLINDED PER PROTOCOL UNTIL FINAL READOUT OF COMPREHENSIVE 18-MONTH DATA
December 18, 2017 EISAI LAUNCHES EDUCATIONAL MATERIALS FOR UNDERSTANDING DEMENTIA AND THINKING ABOUT WHAT ONE CAN DO FOR ELEMENTARY AND SECONDARY SCHOOL STUDENTS IN JAPAN
December 13, 2017 ARICEPT® APPROVED FOR ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE IN CHINA
December 8, 2017 UPDATED ANALYSIS OF PHASE Ib/II STUDY OF ERIBULIN AND PEMBROLIZUMAB COMBINATION REGIMEN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
December 6, 2017 EISAI SUBMITS APPLICATION FOR EXPANDED INDICATION COVERING HEPATOCELLULAR CARCINOMA FOR ANTICANCER AGENT LENVIMA® IN TAIWAN
November 29, 2017 RESUBMITTED NDA FOR ANTICANCER AGENT HALAVEN® ACCEPTED IN CHINA
November 24, 2017 EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT 71ST AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
November 20, 2017 EISAI RECEIVES IT BUSINESS AWARD FOR MEDICATION ADMINISTRATION SUPPORT DEVICE e-OKUSURI-SAN® EQUIPPED WITH FUNCTIONS TO SUPPORT LOOKING AFTER PATIENTS
November 17, 2017 ANTIEPILEPTIC DRUG FYCOMPA® REGULARLY AVAILABLE AGAIN IN GERMANY FROM DECEMBER FOLLOWING AGREEMENT WITH NATIONAL ASSOCIATION OF STATUTORY HEALTH INSURANCE FUNDS
November 6, 2017 NEW DATA FROM LONG-TERM EXTENSION OF PHASE 1b STUDY OF INVESTIGATIONAL ALZHEIMER'S DISEASE TREATMENT ADUCANUMAB PRESENTED AT 10TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE
October 31, 2017 NEW DRUG APPLICATION OF ANTICANCER AGENT LENVATINIB FOR HEPATOCELLULAR CARCINOMA ACCEPTED IN CHINA
October 31, 2017 NEW DRUG APPLICATION OF ANTICANCER AGENT LENVATINIB FOR HEPATOCELLULAR CARCINOMA ACCEPTED IN CHINA
October 31, 2017 EISAI TO PRESENT LATEST DATA AT 10TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE
October 26, 2017 Notification Regarding Revision of Consolidated Financial Forecasts (IFRS)
October 23, 2017 BIOGEN AND EISAI EXPAND EXISTING COLLABORATION AGREEMENT TO DEVELOP AND COMMERCIALIZE INVESTIGATIONAL ALZHEIMER'S DISEASE TREATMENTS INCLUDING PHASE 3 ADUCANUMAB
October 13, 2017 TRANSFER OF RIGHTS TO ANTI-RHEUMATIC AGENT KOLBET® TABLETS 25 MG IN JAPAN
October 10, 2017 SMALL AND EASY TO TAKE, JUST ONE TABLET PER DOSE EISAI TO LAUNCH “ONJI-NO-MEGUMI” FOR IMPROVING FORGETFULNESS IN MIDDLE AGE AND BEYOND
SUPPORTING THE POWER OF MEMORY
October 4, 2017 EISAI AND BIOTOSCANA SIGN EXCLUSIVE LICENSING AGREEMENT FOR LATIN AMERICA
October 3, 2017 SATO PHARMACEUTICAL AND EISAI TO CO-PROMOTE NEW ORAL ANTIFUNGAL AGENT CONTAINING ACTIVE INGREDIENT FOSRAVUCONAZOLE IN JAPAN
September 29, 2017 EISAI PRESENTS RESULTS OF PHASE III TRIAL OF LENVIMA® (LENVATINIB) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN ORAL SESSION AT 20TH CSCO ANNUAL MEETING
RESULTS OF SUBPOPULATION ANALYSIS OF PATIENTS FROM GREATER CHINESE REGION (MAINLAND CHINA, HONG KONG, AND TAIWAN)
September 27, 2017 APPLICATION FOR ADDITIONAL INDICATION OF LENVIMA® FOR HEPATOCELLULAR CARCINOMA ACCEPTED FOR REVIEW BY U.S. FDA
September 25, 2017 EISAI TO CONTRIBUTE TO CENTRAL MEXICAN EARTHQUAKE RELIEF EFFORTS
September 22, 2017 Additional Dosage and Administration of Proton Pump Inhibitor Pariet® 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
September 22, 2017 EISAI PRESENTS LATEST NON-CLINICAL DATA ON ITS FIRST ANTIBODY-DRUG CONJUGATE MORAB-202 AT 8th ANNUAL WORLD ADC
September 19, 2017 EISAI PRESENTS RESULTS OF PHASE III CLINICAL STUDY OF LENVIMA® (LENVATINIB) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA AT 11TH ILCA ANNUAL CONFERENCE
RESULTS OF SUBPOPULATION ANALYSIS OF PATIENTS WITH HEPATITIS B VIRUS COINFECTION
September 13, 2017 THE ANSWER TO VIRUSES AND BACTERIA IN THE HOME! ELIMINATES VIRUSES & BACTERIA, ANTIMICROBIAL ACTION THAT LASTS FOR 1 WEEK EISAI TO LAUNCH NEW “ETAK® ANTIMICROBIAL SPRAYα” CONTAINING LONG-ACTING ANTIMICROBIAL AGENT ETAK®
September 12, 2017 EISAI AND MAMORIO TO JOINTLY LAUNCH “ME-MAMORIO” TRACKING TOOL TO SUPPORT PEOPLE WITH DEMENTIA AND SENIORS GOING OUT
September 11, 2017 EISAI SELECTED FOR FIFTH CONSECUTIVE YEAR OF MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2017
September 11, 2017 EISAI PRESENTS NEW QUALITY OF LIFE FINDINGS IN HEPATOCELLULAR CARCINOMA PATIENTS FROM LENVATINIB VERSUS SORAFENIB STUDY IN ORAL SESSION AT ESMO CONGRESS
September 11, 2017 EISAI PRESENTS RESULTS OF PHASE Ib/II CLINICAL STUDY OF LENVIMA® (LENVATINIB) IN COMBINATION WITH PEMBROLIZUMAB FOR RENAL CELL CARCINOMA IN ORAL SESSION AT ESMO 2017 CONGRESS
September 8, 2017 EISAI LAUNCHES VITAMIN B2 TABLET “CHOCOLA BB® PLUS” IN TAIWAN
FIRST LAUNCH AIMED AT EXPANSION IN ASIA
September 8, 2017 CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR LENVIMA® (LENVATINIB MESYLATE) AND OPDIVO® (NIVOLUMAB) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA
September 6, 2017 EISAI SIGNS AGREEMENT WITH MERCK & CO., INC., KENILWORTH, NJ, USA TO EXPAND ENROLLMENT OF STUDY FOR HALAVEN® (ERIBULIN) AND PEMBROLIZUMAB COMBINATION DUE TO ENCOURAGING INITIAL DATA IN TRIPLE-NEGATIVE BREAST CANCER
September 6, 2017 EISAI SIGNS AGREEMENT WITH MERCK & CO., INC., KENILWORTH, NJ, USA TO EXPAND ENROLLMENT OF COMBINATION STUDY FOR LENVIMA® (LENVATINIB) AND PEMBROLIZUMAB DUE TO ENCOURAGING INITIAL DATA IN ENDOMETRIAL CARCINOMA
September 1, 2017 EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO 2017 CONGRESS
THREE ABSTRACTS ON LENVIMA® (LENVATINIB) TO BE PRESENTED IN ORAL SESSION
August 2, 2017 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 27, 2017 U.S. FDA APPROVES ADDITIONAL USE OF ANTIEPILEPTIC DRUG FYCOMPA® AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES
July 25, 2017 EISAI SUBMITS SIMULTANEOUS APPLICATIONS IN THE UNITED STATES AND EUROPE FOR LENVATINIB IN HEPATOCELLULAR CARCINOMA
July 3, 2017 WELLNESS OPEN LIVING LABS. LLC, CO-FOUNDED BY EISAI, AND OSAKA CITY UNIVERSITY CONCLUDE BASIC COLLABORATION AGREEMENT AIMED AT SOLVING HEALTH PROBLEMS
June 30, 2017 Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
June 28, 2017 EISAI LISTED FOR 16TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
June 27, 2017 EISAI TEMPORARILY WITHDRAWS NEW DRUG APPLICATION FOR ANTICANCER AGENT HALAVEN® IN CHINA
PLANS TO RESUBMIT APPLICATION AFTER PREPARING ADDITIONAL DOCUMENTATION
June 23, 2017 EISAI SUBMITS APPLICATION FOR ADDITIONAL INDICATION OF ANTICANCER AGENT LENVIMA® FOR HEPATOCELLULAR CARCINOMA IN JAPAN
June 22, 2017 CARDIOVASCULAR OUTCOMES TRIAL OF ANTI-OBESITY AGENT LORCASERIN TO CONTINUE BASED ON RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE AFTER COMPLETION OF INTERIM SAFETY ANALYSIS
June 8, 2017 LAUNCH OF PAIN TREATMENT LYRICA® OD TABLET FORMULATION IN JAPAN
June 5, 2017 EISAI TO PRESENT RESULTS OF PHASE III TRIAL OF LENVIMA® (LENVATINIB) AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN ORAL SESSION AT 53RD ASCO ANNUAL MEETING
PRIMARY ENDPOINT ACHIEVED AND STATISTICALLY SIGNIFICANT IMPROVEMENT OF SECONDARY ENDPOINTS COMPARED WITH SORAFENIB
June 5, 2017 EISAI TO PRESENT RESULTS OF PHASE Ib/II STUDY OF ANTICANCER AGENT LENVIMA® (LENVATINIB) IN COMBINATION WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB FOR THE TREATMENT OF ENDOMETRIAL CARCINOMA AT 53RD ASCO ANNUAL MEETING
June 1, 2017 INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA
EISAI COMMITS FUNDING TO THE 2ND PHASE OF GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND ACTIVITIES
May 31, 2017 EISAI ENTERS INTO A NEW JOINT RESEARCH AGREEMENT WITH THE BROAD INSTITUTE TO DEVELOP AN ANTIMALARIAL MEDICINE
May 18, 2017 EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 53RD ASCO ANNUAL MEETING
RESULTS OF STUDY OF LENVIMA® (LENVATINIB) IN HEPATOCELLULAR CARCINOMA TO BE PRESENTED IN ORAL SESSION
May 10, 2017 Proposed Changes in Representative Officers
May 3, 2017 PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES
April 19, 2017 EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF LYMPHATIC FILARIASIS
5 YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES
April 11, 2017 SPEEDY CARE TO RELIEVE FATIGUE! EISAI TO LAUNCH “CHOCOLA BB® GOLD RICH”HIGHEST COMBINATION OF ACTIVE INGREDIENTS IN CHOCOLA BB SERIES
EASY TO DRINK BERGAMOT FLAVOR
April 5, 2017 EISAI AND MEIJI ENTER INTO LICENSING AGREEMENT CONCERNING PARKINSON'S DISEASE DRUG SAFINAMIDE IN JAPAN AND ASIA
April 5, 2017 EISAI PRESENTS DATA OF MECHANISMS OF ACTION RELATING TO TUMOR IMMUNE RESPONSE REGARDING COMBINATION OF ANTICANCER AGENT LENVATINIB WITH ANTI-PD-1 ANTIBODY AT AACR 108TH ANNUAL MEETING
April 3, 2017 EISAI TO LAUNCH SMELL IDENTIFICATION TEST UPSIT SERIES IN JAPAN
March 29, 2017 ENROLLMENT COMMENCES IN PHASE III CLINICAL STUDY OF EISAI'S BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER'S DISEASE IN JAPAN
March 28, 2017 GERMAN FEDERAL JOINT COMMITTEE (G-BA) CONFIRMS ADDITIONAL BENEFIT OF ANTICANCER AGENT KISPLYX® (LENVATINIB MESYLATE) IN TREATMENT OF ADVANCED RENAL CELL CARCINOMA
February 21, 2017 APPROVAL RECEIVED FOR PAIN TREATMENT LYRICA® OD TABLET FORMULATION IN JAPAN
February 16, 2017 EISAI ENTERS INTO MARKETING AND DISTRIBUTION AGREEMENT WITH ORION CONCERNING PARKINSON'S DISEASE DRUGS IN CHINA
January 25, 2017 PHASE III TRIAL OF ANTICANCER AGENT LENVIMA® AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA MEETS PRIMARY ENDPOINT
January 24, 2017 EISAI SELECTED FOR EXCELLENCE IN SUSTAINABILITY PERFORMANCE AND INDUSTRY MOVER DISTINCTION BY ROBECOSAM, A LEADING ASSESSOR OF SOCIAL RESPONSIBILITY INVESTMENT
January 18, 2017 EISAI TO PARTICIPATE IN ACCESS ACCELERATED,GLOBAL PARTNERSHIP TO ADDRESS RISE OF NON-COMMUNICABLE DISEASES
ACCELERATING ACCESS TO HEALTH CARE IN LOW AND LOWER-MIDDLE INCOME COUNTRIES
January 16, 2017 TRANSFER OF RIGHTS TO INSOMNIA TREATMENT / ANAESTHESIA INDUCTION AGENT FLUNITRAZEPAM IN JAPAN
January 12, 2017 EISAI TO LAUNCH MEDICATION ADMINISTRATION SUPPORT DEVICE e-OKUSURI-SAN®
EQUIPPED WITH FUNCTIONS TO SUPPORT LOOKING AFTER PATIENTS
January 5, 2017 EISAI ACQUIRES ALL GLOBAL DEVELOPMENT AND MARKETING RIGHTS FOR CHRONIC WEIGHT MANAGEMENT TREATMENT LORCASERIN

Back to Top